Posted by SLS on June 2, 2001, at 22:53:59
In reply to Re: Studies: New Celexa promising » Rick, posted by Mitch on June 1, 2001, at 23:26:59
> I saw a Medline abstract months ago talking about the pharmacologically active metabolite of nortiptyline (Pamelelor) 10-hydroxy-nortriptyine as having serotonin down-regulation effect and anxiolytic effects. They mentioned that it ought to be pursued as a possible separate med to develop.
Mitch - can you recall about when the article regarding nortriptyline was published?
> > Does anyone know if any other AD's have similarly refined versions in the works?
A refined version of Prozac, r-fluoxetine, was being developed by Lilly, the manufacturer of Prozac, in conjunction with Sepracor, a company specialized in synthesizing and isolating enantiomers. It was touted as being as effective as Prozac, but with a possibly more benign side effect profile. Unfortunately for the two companies, cardiovascular side effects emerged in phase III trials, and the project was abandoned. Prolonged QTc intervals were observed at the highest dosage tested. They probably should have tested it at half the dosage, as it would seem to me that it would be twice as potent as the racemate (r+s combination). Anyway, Sepracor and other drug manufacturers are pursuing refined versions (called ICEs - Improved Chemical Entities) of currently marketed antidepressants. Escitalopram (s-citalopram) is an example of one. From the URL Rick posted, it looks exciting.
> Also, about a year ago, I read about testing on a new version of Valium without the side effects and dependence or addiction risks.
Did this involve the identification of a benzodiazepine receptor domain subtype?
Thanks.
- Scott
poster:SLS
thread:64685
URL: http://www.dr-bob.org/babble/20010530/msgs/65215.html